| Type size: |
 |
 |
|
|
Novel Drug Testing Services
Early Lead Identification and Optimization
The discovery of novel drug compounds effective against HIV requires experience
and technology that extends beyond the capabilities of most clinical laboratories.
Monogram has the tools and expertise to help pharmaceutical and biotech companies
optimize their pre-clinical and clinical drug development programs through early lead drug
identification, lead candidate selection and characterization throughout clinical development.
PhenoSense™ and PhenoScreen™ technologies provide a better understanding of a novel compound's potential benefits based on its activity against a wide range of real-world viruses and specific mutational patterns, as compared with other drugs in the same class.
Monogram can also build site-directed mutants (SDMs) and incorporate them into a panel of viruses to be tested against a set of novel compounds.
Novel drug testing services include access to Monogram scientists for study design and data interpretation.
PhenoSense Customized Novel Drug Testing
-
The most precise and extensive assessment of drug susceptibility for identified
drug candidates
-
State-of-the-Art PhenoSence assay format
-
Fully customized virus panels
-
Highly accurate IC50
values and fold changes relative to control viruses
-
Addresses pre-IND and clinical trial regulatory requirements
PhenoScreen High-Throughput Novel Drug Screening
-
Optimal method for evaluating large numbers of candidate compounds
-
Rapid testing 10 to hundreds of compounds
-
Drug activity assessed against a panel of drug-sensitive and multi-drug
resistant viruses
-
Approximate IC50
values and fold changes relative to control viruses
-
Cost-efficient method for preclinical development
Drug Profiling
As part of the Novel
Drug offering, clients also have the option to include their novel
compound in Monogram's standard PhenoSense PR/RT panel during routine clinical
lab testing. The novel drug data are reported only to the submitting client
along with the daily PhenoSense results thereby providing a direct comparison
of the novel compound to all commercially available drugs.
Reference: Bethell, R. C., Lie Y. S., Parkin, NT.
In Vitro Activity of SPD754, A New Deoxycytidine Nucleoside Reverse
Transcriptase Inhibitor (NRTI), Against 215 HIV-1 Isolates Resistant to Other
NRTIs.
Examples of our drug testing data:
-
GS9148: A Novel Nucleotide Active Against HIV-1 Variants with Drug Resistance
Mutations in Reverse Transcriptase.
Cihlar, T., Ray, A., Boojamra, D., Zhang, L., Hui, H., Grant, D., White, K.,
Desai, M., Parkin, N., and Mackman, R. (Gilead)
-
Antiviral activity of SPI-256 against WT and MDR strains.
SV Gulnik, E Afonina, M Eissenstat, H Yokoe, B. Yu, M Markowitz, NT Parkin and
JW Erickson (Sequoia)
For more information on Monogram assays, services and pricing, please contact us.
|
|
